Description
Summary Abstract
Human chorionic gonadotropin (HCG) is a heterodimeric glycoprotein hormone of the cystine-knot family, composed of a non-covalently associated α-subunit (92 amino acids, shared with LH, FSH, and TSH) and a unique, highly glycosylated β-subunit (145 amino acids) that confers receptor specificity. The β-subunit contains a 24-amino-acid C-terminal extension absent in luteinizing hormone (LH), which increases sialylation and extends the serum half-life of HCG (t½ ~24 hours) relative to LH (t½ ~60 minutes). HCG binds with high affinity to the LH/chorionic gonadotropin receptor (LHCGR), a G-protein–coupled receptor expressed on testicular Leydig cells, ovarian theca cells, granulosa cells, and the corpus luteum. Through LHCGR-mediated cAMP signaling, HCG stimulates gonadal steroidogenesis — primarily testosterone production in males and progesterone and estrogen synthesis in females — making it a foundational research and clinical tool in reproductive endocrinology, gonadotropin biology, and male hormonal axis investigation.
Clinical Indications
HCG is investigated and applied across reproductive endocrinology and gonadal function research:
- Male hypogonadism and testicular steroidogenesis: HCG serves as the reference standard LH surrogate for stimulating Leydig cell testosterone production; used to assess Leydig cell reserve (HCG stimulation test), support testosterone production during HPG-axis suppression, and model gonadotropin-dependent hypogonadism.
- Ovulation induction and assisted reproduction: HCG triggers the LH-like ovulatory surge in follicle-stimulating hormone (FSH)–primed ovarian cycles; the HCG trigger is mechanistically equivalent to the endogenous LH surge for final oocyte maturation and ovulation.
- Corpus luteum support and luteal phase research: HCG sustains corpus luteum progesterone secretion via LHCGR on granulosa-lutein cells; critical for luteal phase adequacy studies and implantation biology research.
Contraindications
- Ovarian hyperstimulation syndrome (OHSS) models: High HCG concentrations in FSH-primed models carry significant OHSS risk through VEGF-driven vascular permeability; this dose-dependent effect must be controlled in high-stimulation ovarian protocols.
- Hormone-sensitive tumor models: LHCGR is expressed on some gonadal tumor cell lines; HCG administration in these contexts will stimulate gonadotropin-responsive proliferative pathways.
- Anti-doping crossover: HCG is prohibited in sport under WADA S2; research involving athletic performance models should document this prohibition and ensure appropriate institutional governance.
Mechanism of Action (MOA)
HCG exerts its gonadotropic effects through high-affinity LHCGR binding and downstream steroidogenic signaling cascades:
LHCGR Binding and cAMP Signaling
HCG binds the luteinizing hormone / chorionic gonadotropin receptor (LHCGR) with high affinity via its β-subunit. LHCGR is a class A G-protein–coupled receptor coupled to Gsα; receptor activation stimulates adenylyl cyclase, increasing intracellular cAMP, which activates PKA-mediated phosphorylation of steroidogenic regulatory proteins including StAR (steroidogenic acute regulatory protein).
Leydig Cell Steroidogenesis (Male)
In testicular Leydig cells, PKA activation via LHCGR phosphorylates StAR, facilitating cholesterol transport to the inner mitochondrial membrane for CYP11A1-mediated conversion to pregnenolone — the rate-limiting step in testosterone biosynthesis. The cascade proceeds through 17α-hydroxylase/17,20-lyase (CYP17A1) to yield testosterone, with a half-life advantage over LH allowing sustained Leydig cell stimulation from a single injection.
Ovarian Steroidogenesis and Ovulation Trigger (Female)
In ovarian theca and granulosa-lutein cells, LHCGR-cAMP signaling drives androstenedione production (theca), aromatization to estradiol (granulosa), and, after ovulation, progesterone secretion by the corpus luteum. The HCG ovulation trigger mimics the endogenous LH surge, inducing final oocyte maturation, cumulus expansion, and follicular rupture within 36–40 hours.
Extended Half-Life via C-Terminal Peptide Sialylation
The β-subunit’s unique C-terminal peptide (CTP) carries four O-linked oligosaccharide chains (at Ser121, Ser127, Ser132, Ser138) providing terminal sialylation that reduces hepatic asialoglycoprotein receptor–mediated clearance. This accounts for the ~24-hour serum half-life of HCG versus ~60 minutes for LH — the structural basis for once-daily or less-frequent dosing in gonadal stimulation research.
Key Features & Specifications
HCG is the gold-standard endogenous LH surrogate for gonadotropin research due to its LHCGR selectivity and extended half-life:
Chemical Analysis
| Property | Specification Reference Data |
|---|---|
| Class | Heterodimeric glycoprotein hormone; cystine-knot family |
| Composition | α-subunit: 92 amino acids (14.9 kDa, N-glycosylated at Asn52, Asn78); β-subunit: 145 amino acids (23 kDa, N-glycosylated at Asn13, Asn30; O-glycosylated at Ser121, Ser127, Ser132, Ser138) |
| Molecular Weight | ~37.9 kDa (native, non-covalent α/β heterodimer) |
| Carbohydrate content | ~31% by weight (high sialylation of β-CTP extends half-life) |
| Serum Half-Life | ~24 hours (vs. ~60 min for LH) |
| Receptor Target | LH/chorionic gonadotropin receptor (LHCGR), a class A GPCR |
| Form / Variation | Standard lyophilized — P-0799796960076879 ($42.00) |
Storage, Safety, and Handling
Storage Protocol
Store lyophilized HCG at 2–8 °C, protected from light and moisture. Upon reconstitution with bacteriostatic water, store reconstituted solution at 2–8 °C and use within 30 days; do not freeze reconstituted glycoprotein. Lyophilized material may be stored at −20 °C for extended shelf life, but avoid repeated freeze-thaw cycling.
Handling & Compliance
Handle as a biological protein product using aseptic technique; use appropriate PPE for reconstitution. HCG is WADA-prohibited (S2 — Peptide Hormones) and classified as a prescription drug in most jurisdictions. Researchers must comply with institutional pharmacy, biosafety, and IRB/IACUC protocols governing use of glycoprotein hormones in research settings.